NEUROTECH INTERNATIONAL LIMITED - Announcements

7.69%

1.4¢

Market Cap $14.69M

Healthcare Biotechnology

Neurotech International Limited is an Australia-based clinical-stage biopharmaceutical... Neurotech International Limited is an Australia-based clinical-stage biopharmaceutical development company. The Company is focused predominately on pediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. It has completed a Phase II/III randomized, double-blind, placebo-controlled clinical trial in autism spectrum disorder (ASD) with clinically significant benefits reported across a number of clinically validated measures and safety. In addition, it has completed and reported significant and clinically meaningful Phase I/II trials in ASD and pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) and pediatric acute-onset neuropsychiatric syndrome (PANS), collectively PANDAS/PANS along with Rett Syndrome. NTI164 is being developed as a therapeutic drug product for a range of neurological disorders in children where neuroinflammation is involved.More

HELPING PATIENTS ON THEIR JOURNEY TO BETTER HEALTH

Little Green Pharma (ASX:LGP) to benefit as Denmark commits to cannabis pilot program.

Announcements

Filter Results

All Price Sensitive Only

NTI	Appendix 4G and Corporate Governance Statement		29/08/25	530.48KB	Share
NTI	Appendix 4E & Annual Report to shareholders	PRICE SENSITIVE	29/08/25	2.03MB	Share
NTI	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/07/25	380.56KB	Share
NTI	Change of Registered Address & Principal Place of Business		10/07/25	83.83KB	Share
NTI	Becoming a substantial holder		09/07/25	171.47KB	Share
NTI	New Scientific Publication of Phase I/II Rett Syndrome Trial		07/07/25	265.77KB	Share
NTI	NTI Appoints Dr. Bonni Goldstein as Chief Medical Advisor		16/06/25	126.5KB	Share
NTI	NTI164 to be presented at IRSF Annual Scientific Meeting		06/06/25	99.98KB	Share
NTI	Positive Human PK Study Results for NTI164	PRICE SENSITIVE	02/06/25	123.18KB	Share
NTI	NTI164 Preclinical Toxicology Studies Update	PRICE SENSITIVE	05/05/25	112.86KB	Share
NTI	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/04/25	314.41KB	Share
NTI	Updated Trading Policy		16/04/25	165.86KB	Share
NTI	Secondary Trading Notice		02/04/25	86.58KB	Share
NTI	Application for quotation of securities - NTI		02/04/25	15.8KB	Share
NTI	Final Director's Interest Notice		02/04/25	151.91KB	Share
NTI	Resignation of Executive Director		01/04/25	101.1KB	Share
NTI	European Commission grants NTI164 ODD for Rett Syndrome		31/03/25	107.49KB	Share
NTI	Retraction of Statement		26/03/25	69.59KB	Share
NTI	New Scientific Publication of Phase I/II Autism Trial		24/03/25	118.05KB	Share
NTI	Neurotech Presentation at NWR Virtual Healthcare Conference		20/03/25	4.94MB	Share
NTI	Neurotech to present at NWR Virtual Healthcare Conference		18/03/25	74.41KB	Share
NTI	Appendix 4D and Half Year Accounts	PRICE SENSITIVE	27/02/25	1006.37KB	Share
NTI	Positive Opinion on OMPD for NTI164 in Europe	PRICE SENSITIVE	27/02/25	119.43KB	Share
NTI	Change of Director's Interest Notice		24/02/25	159.27KB	Share
NTI	Notification regarding unquoted securities - NTI		24/02/25	22.35KB	Share
NTI	NTI Signs Development Agreement for Cannabinoid Therapies	PRICE SENSITIVE	13/02/25	127.25KB	Share
NTI	Initial Director's Interest Notice		04/02/25	139.54KB	Share
NTI	Neurotech Receives $2.44 Million R&D Tax Incentive Refund	PRICE SENSITIVE	31/01/25	134.52KB	Share
NTI	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	29/01/25	349.64KB	Share
NTI	Notice of Expiry of Listed Options		17/12/24	150.08KB	Share
NTI	Becoming a substantial holder		12/12/24	266.02KB	Share
NTI	Change of Director's Interest Notice		06/12/24	177.41KB	Share
NTI	Resignation of Joint Company Secretary		02/12/24	83.84KB	Share
NTI	Secondary Trading Notice		02/12/24	84.39KB	Share
NTI	Application for quotation of securities - NTI		02/12/24	15.79KB	Share
NTI	Neurotech Receives US ODD in Rett Syndrome	PRICE SENSITIVE	26/11/24	127.66KB	Share
NTI	NTI Receives Ethics Approval to Commence Human PK Study	PRICE SENSITIVE	25/11/24	129.34KB	Share
NTI	Notification of cessation of securities - NTI		20/11/24	12.88KB	Share
NTI	Results of Annual General Meeting		20/11/24	94.16KB	Share
NTI	2024 AGM Chairman Address and Investor Presentation		20/11/24	1.25MB	Share
NTI	Positive Genomic Effects of NTI164 in PANDAS/PANS Patients	PRICE SENSITIVE	15/11/24	211KB	Share
NTI	New Scientific Publication Highlights Benefits of NTI164		12/11/24	159.89KB	Share
NTI	Proposed issue of securities - NTI		11/11/24	19.83KB	Share
NTI	Neurotech Appoints Dr Anthony Filippis as MD/CEO	PRICE SENSITIVE	11/11/24	118.54KB	Share
NTI	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	23/10/24	410.52KB	Share
NTI	Notice of Annual General Meeting/Proxy Form		16/10/24	483.01KB	Share
NTI	Becoming a substantial holder		08/10/24	120.58KB	Share
NTI	US FDA Response to Orphan Drug Request in PANDAS/PANS	PRICE SENSITIVE	04/10/24	103.42KB	Share
NTI	Upcoming Presentation of Rett Syndrome Clinical Data		24/09/24	169.66KB	Share
NTI	Change of Director's Interest Notice		20/09/24	138.88KB	Share
NTI	Notification regarding unquoted securities - NTI		20/09/24	14.48KB	Share
NTI	Notification of cessation of securities - NTI		18/09/24	13.05KB	Share
NTI	Secondary Trading Notice		18/09/24	99.62KB	Share
NTI	Notification regarding unquoted securities - NTI		18/09/24	18.16KB	Share
NTI	Application for quotation of securities - NTI		18/09/24	16.04KB	Share
NTI	Becoming a substantial holder		17/09/24	164.63KB	Share
NTI	Ceasing to be a substantial holder		17/09/24	147.22KB	Share
NTI	Application for quotation of securities - NTI		17/09/24	15.59KB	Share
NTI	Results of General Meeting		10/09/24	94.14KB	Share
NTI	NTI164 Reverses Immune Dysregulation in PANDAS/PANS Children	PRICE SENSITIVE	09/09/24	160.17KB	Share
NTI	Neurotech ESG Report		30/08/24	1.17MB	Share
NTI	US FDA orphan drug designation requested for Rett Syndrome		30/08/24	105.58KB	Share
NTI	Secondary Trading Notice		27/08/24	70.3KB	Share
NTI	Application for quotation of securities - NTI		27/08/24	15.58KB	Share
NTI	Appendix 4G and Corporate Governance Statement		26/08/24	489.94KB	Share
NTI	Appendix 4E & Annual Report to shareholders	PRICE SENSITIVE	26/08/24	8.99MB	Share
NTI	Neurotech to present at Investor Verse Biotech Workshop		13/08/24	1.46MB	Share
NTI	Neurotech Global Partnering and Registration Strategy	PRICE SENSITIVE	12/08/24	185.09KB	Share
NTI	Notice of General Meeting/Proxy Form		09/08/24	505.39KB	Share
NTI	Further Significant Improvement in Rett Syndrome Patients	PRICE SENSITIVE	31/07/24	297.53KB	Share
NTI	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	25/07/24	671.56KB	Share
NTI	Phase II/III autism trial shows further benefits	PRICE SENSITIVE	18/07/24	194.28KB	Share
NTI	Investor Presentation		10/07/24	1.55MB	Share
NTI	Significant improvement in Autism patients at 12 weeks	PRICE SENSITIVE	10/07/24	347.14KB	Share
NTI	US FDA orphan drug designation requested for PANDAS/PANS		09/07/24	106.33KB	Share
NTI	Appointment of Chief Medical Officer		05/07/24	140.64KB	Share
NTI	Release of Shares from Voluntary Escrow		01/07/24	82.77KB	Share
NTI	Expert PANDAS/PANS panel established post TGA meeting		28/06/24	139.08KB	Share
NTI	Investor Presentation		17/06/24	2.29MB	Share
NTI	Phase I/II Autism Patients Meet 2 Years of NTI164 Treatment	PRICE SENSITIVE	17/06/24	190.62KB	Share
NTI	Further clinical benefit at 52 weeks in PANDAS/PANS patients	PRICE SENSITIVE	06/06/24	190.18KB	Share
NTI	NTI Formalises Strategic Partnership with Fenix Innovation		03/06/24	146.77KB	Share
NTI	Notice of Change of Auditor		08/05/24	83.71KB	Share
NTI	Change of Director's Interest Notice		08/05/24	1.08MB	Share
NTI	Investor Webinar on Rett Syndrome Clinical Trial Results		06/05/24	85.16KB	Share
NTI	Investor Presentation		06/05/24	1.77MB	Share
NTI	Rett Syndrome Phase I/II trial shows significant benefits	PRICE SENSITIVE	06/05/24	593.85KB	Share
NTI	Trading Halt	PRICE SENSITIVE	03/05/24	140.26KB	Share
NTI	Neurotech Receives $10 Million in Placement Funds		24/04/24	83.91KB	Share
NTI	Notification regarding unquoted securities - NTI		24/04/24	17.64KB	Share
NTI	Secondary Trading Notice		24/04/24	91.73KB	Share
NTI	Application for quotation of securities - NTI		24/04/24	15.81KB	Share
NTI	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	23/04/24	445.81KB	Share
NTI	Initial Director's Interest Notice		19/04/24	125.34KB	Share
NTI	Final Director's Interest Notice		19/04/24	130.37KB	Share
NTI	Proposed issue of securities - NTI		19/04/24	16.84KB	Share
NTI	Board Changes		19/04/24	102.61KB	Share
NTI	Investor Presentation		17/04/24	2.32MB	Share
NTI	Proposed issue of securities - NTI		17/04/24	18.84KB	Share
NTI	Neurotech Completes $10 Million Capital Raise	PRICE SENSITIVE	17/04/24	193.4KB	Share

NTI Appendix 4G and Corporate Governance Statement
29/08/25		530.48KB	Share
NTI Appendix 4E & Annual Report to shareholders
29/08/25	PRICE SENSITIVE	2.03MB	Share
NTI Quarterly Activities/Appendix 4C Cash Flow Report
31/07/25	PRICE SENSITIVE	380.56KB	Share
NTI Change of Registered Address & Principal Place of Business
10/07/25		83.83KB	Share
NTI Becoming a substantial holder
09/07/25		171.47KB	Share
NTI New Scientific Publication of Phase I/II Rett Syndrome Trial
07/07/25		265.77KB	Share
NTI NTI Appoints Dr. Bonni Goldstein as Chief Medical Advisor
16/06/25		126.5KB	Share
NTI NTI164 to be presented at IRSF Annual Scientific Meeting
06/06/25		99.98KB	Share
NTI Positive Human PK Study Results for NTI164
02/06/25	PRICE SENSITIVE	123.18KB	Share
NTI NTI164 Preclinical Toxicology Studies Update
05/05/25	PRICE SENSITIVE	112.86KB	Share
NTI Quarterly Activities/Appendix 4C Cash Flow Report
28/04/25	PRICE SENSITIVE	314.41KB	Share
NTI Updated Trading Policy
16/04/25		165.86KB	Share
NTI Secondary Trading Notice
02/04/25		86.58KB	Share
NTI Application for quotation of securities - NTI
02/04/25		15.8KB	Share
NTI Final Director's Interest Notice
02/04/25		151.91KB	Share
NTI Resignation of Executive Director
01/04/25		101.1KB	Share
NTI European Commission grants NTI164 ODD for Rett Syndrome
31/03/25		107.49KB	Share
NTI Retraction of Statement
26/03/25		69.59KB	Share
NTI New Scientific Publication of Phase I/II Autism Trial
24/03/25		118.05KB	Share
NTI Neurotech Presentation at NWR Virtual Healthcare Conference
20/03/25		4.94MB	Share
NTI Neurotech to present at NWR Virtual Healthcare Conference
18/03/25		74.41KB	Share
NTI Appendix 4D and Half Year Accounts
27/02/25	PRICE SENSITIVE	1006.37KB	Share
NTI Positive Opinion on OMPD for NTI164 in Europe
27/02/25	PRICE SENSITIVE	119.43KB	Share
NTI Change of Director's Interest Notice
24/02/25		159.27KB	Share
NTI Notification regarding unquoted securities - NTI
24/02/25		22.35KB	Share
NTI NTI Signs Development Agreement for Cannabinoid Therapies
13/02/25	PRICE SENSITIVE	127.25KB	Share
NTI Initial Director's Interest Notice
04/02/25		139.54KB	Share
NTI Neurotech Receives $2.44 Million R&D Tax Incentive Refund
31/01/25	PRICE SENSITIVE	134.52KB	Share
NTI Quarterly Activities/Appendix 4C Cash Flow Report
29/01/25	PRICE SENSITIVE	349.64KB	Share
NTI Notice of Expiry of Listed Options
17/12/24		150.08KB	Share
NTI Becoming a substantial holder
12/12/24		266.02KB	Share
NTI Change of Director's Interest Notice
06/12/24		177.41KB	Share
NTI Resignation of Joint Company Secretary
02/12/24		83.84KB	Share
NTI Secondary Trading Notice
02/12/24		84.39KB	Share
NTI Application for quotation of securities - NTI
02/12/24		15.79KB	Share
NTI Neurotech Receives US ODD in Rett Syndrome
26/11/24	PRICE SENSITIVE	127.66KB	Share
NTI NTI Receives Ethics Approval to Commence Human PK Study
25/11/24	PRICE SENSITIVE	129.34KB	Share
NTI Notification of cessation of securities - NTI
20/11/24		12.88KB	Share
NTI Results of Annual General Meeting
20/11/24		94.16KB	Share
NTI 2024 AGM Chairman Address and Investor Presentation
20/11/24		1.25MB	Share
NTI Positive Genomic Effects of NTI164 in PANDAS/PANS Patients
15/11/24	PRICE SENSITIVE	211KB	Share
NTI New Scientific Publication Highlights Benefits of NTI164
12/11/24		159.89KB	Share
NTI Proposed issue of securities - NTI
11/11/24		19.83KB	Share
NTI Neurotech Appoints Dr Anthony Filippis as MD/CEO
11/11/24	PRICE SENSITIVE	118.54KB	Share
NTI Quarterly Activities/Appendix 4C Cash Flow Report
23/10/24	PRICE SENSITIVE	410.52KB	Share
NTI Notice of Annual General Meeting/Proxy Form
16/10/24		483.01KB	Share
NTI Becoming a substantial holder
08/10/24		120.58KB	Share
NTI US FDA Response to Orphan Drug Request in PANDAS/PANS
04/10/24	PRICE SENSITIVE	103.42KB	Share
NTI Upcoming Presentation of Rett Syndrome Clinical Data
24/09/24		169.66KB	Share
NTI Change of Director's Interest Notice
20/09/24		138.88KB	Share
NTI Notification regarding unquoted securities - NTI
20/09/24		14.48KB	Share
NTI Notification of cessation of securities - NTI
18/09/24		13.05KB	Share
NTI Secondary Trading Notice
18/09/24		99.62KB	Share
NTI Notification regarding unquoted securities - NTI
18/09/24		18.16KB	Share
NTI Application for quotation of securities - NTI
18/09/24		16.04KB	Share
NTI Becoming a substantial holder
17/09/24		164.63KB	Share
NTI Ceasing to be a substantial holder
17/09/24		147.22KB	Share
NTI Application for quotation of securities - NTI
17/09/24		15.59KB	Share
NTI Results of General Meeting
10/09/24		94.14KB	Share
NTI NTI164 Reverses Immune Dysregulation in PANDAS/PANS Children
09/09/24	PRICE SENSITIVE	160.17KB	Share
NTI Neurotech ESG Report
30/08/24		1.17MB	Share
NTI US FDA orphan drug designation requested for Rett Syndrome
30/08/24		105.58KB	Share
NTI Secondary Trading Notice
27/08/24		70.3KB	Share
NTI Application for quotation of securities - NTI
27/08/24		15.58KB	Share
NTI Appendix 4G and Corporate Governance Statement
26/08/24		489.94KB	Share
NTI Appendix 4E & Annual Report to shareholders
26/08/24	PRICE SENSITIVE	8.99MB	Share
NTI Neurotech to present at Investor Verse Biotech Workshop
13/08/24		1.46MB	Share
NTI Neurotech Global Partnering and Registration Strategy
12/08/24	PRICE SENSITIVE	185.09KB	Share
NTI Notice of General Meeting/Proxy Form
09/08/24		505.39KB	Share
NTI Further Significant Improvement in Rett Syndrome Patients
31/07/24	PRICE SENSITIVE	297.53KB	Share
NTI Quarterly Activities/Appendix 4C Cash Flow Report
25/07/24	PRICE SENSITIVE	671.56KB	Share
NTI Phase II/III autism trial shows further benefits
18/07/24	PRICE SENSITIVE	194.28KB	Share
NTI Investor Presentation
10/07/24		1.55MB	Share
NTI Significant improvement in Autism patients at 12 weeks
10/07/24	PRICE SENSITIVE	347.14KB	Share
NTI US FDA orphan drug designation requested for PANDAS/PANS
09/07/24		106.33KB	Share
NTI Appointment of Chief Medical Officer
05/07/24		140.64KB	Share
NTI Release of Shares from Voluntary Escrow
01/07/24		82.77KB	Share
NTI Expert PANDAS/PANS panel established post TGA meeting
28/06/24		139.08KB	Share
NTI Investor Presentation
17/06/24		2.29MB	Share
NTI Phase I/II Autism Patients Meet 2 Years of NTI164 Treatment
17/06/24	PRICE SENSITIVE	190.62KB	Share
NTI Further clinical benefit at 52 weeks in PANDAS/PANS patients
06/06/24	PRICE SENSITIVE	190.18KB	Share
NTI NTI Formalises Strategic Partnership with Fenix Innovation
03/06/24		146.77KB	Share
NTI Notice of Change of Auditor
08/05/24		83.71KB	Share
NTI Change of Director's Interest Notice
08/05/24		1.08MB	Share
NTI Investor Webinar on Rett Syndrome Clinical Trial Results
06/05/24		85.16KB	Share
NTI Investor Presentation
06/05/24		1.77MB	Share
NTI Rett Syndrome Phase I/II trial shows significant benefits
06/05/24	PRICE SENSITIVE	593.85KB	Share
NTI Trading Halt
03/05/24	PRICE SENSITIVE	140.26KB	Share
NTI Neurotech Receives $10 Million in Placement Funds
24/04/24		83.91KB	Share
NTI Notification regarding unquoted securities - NTI
24/04/24		17.64KB	Share
NTI Secondary Trading Notice
24/04/24		91.73KB	Share
NTI Application for quotation of securities - NTI
24/04/24		15.81KB	Share
NTI Quarterly Activities/Appendix 4C Cash Flow Report
23/04/24	PRICE SENSITIVE	445.81KB	Share
NTI Initial Director's Interest Notice
19/04/24		125.34KB	Share
NTI Final Director's Interest Notice
19/04/24		130.37KB	Share
NTI Proposed issue of securities - NTI
19/04/24		16.84KB	Share
NTI Board Changes
19/04/24		102.61KB	Share
NTI Investor Presentation
17/04/24		2.32MB	Share
NTI Proposed issue of securities - NTI
17/04/24		18.84KB	Share
NTI Neurotech Completes $10 Million Capital Raise
17/04/24	PRICE SENSITIVE	193.4KB	Share

REFRESH

1 2 3 4 5 6

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 1.4¢		Change 0.001(7.69%)		Mkt cap ! $14.69M

Open	High	Low	Value	Volume
1.3¢	1.4¢	1.3¢	$4.026K	307.2K

Buyers (Bids)

No.	Vol.	Price($)
1	1917576	1.3¢

Sellers (Offers)

Price($)	Vol.	No.
1.4¢	505017	5

View Market Depth

No.	Vol.	Price($)
1	1917576	0.013
11	3680644	0.012
10	2248075	0.011
8	2120000	0.010
2	159000	0.009

Price($)	Vol.	No.
0.014	505017	5
0.015	1025224	4
0.016	689340	9
0.017	268623	2
0.018	563001	4

Last trade - 16.10pm 29/08/2025 (20 minute delay)

NTI (ASX) Chart

NEUROTECH INTERNATIONAL LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories